NUNZ.US Nunzia Pharmaceutical Corporation
- Market cap
- USD 43.5K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is NUNZ.US undervalued?
Graham numberThe Graham number of Nunzia Pharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nunzia Pharmaceutical Corporation fundamental analysis
No fundamental analysis for Nunzia Pharmaceutical Corporation yet.
Nunzia Pharmaceutical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nunzia Pharmaceutical Corporation
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nun…
Full company profileNunzia Pharmaceutical Corporation financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nunzia Pharmaceutical Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2006 | 2007 | 2009 | 2010 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Gross Profit | - | - | - | -15.0K | - | - | - | - | - | - | - |
| Operating Income | -163K | -148K | -65.0K | 268K | -326K | -27.2K | -33.6K | -16.3K | -78.1M | - | - |
| EBITDA | - | - | - | - | -13.0K | -18.6K | -33.6K | - | -9.04M | - | - |
| Net Income | -163K | -148K | -65.0K | 268K | -326K | -18.6K | -33.6K | -9.02M | -78.1M | - | - |
| EPS | -10 | -9.20 | -40 | - | 0.00 | 0.00 | 0.00 | -0.04 | -0.26 | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 6.00K | 6.00K | - | 1.48B | 6.00K | 0.00 | 0.00 | 0.00 | 5.13K | - | 35.4K |
| Total Liabilities | 3.48M | 3.60M | 3.88M | 55.6K | 275K | 294K | 22.6K | 36.4K | 99.3K | - | 227K |
| Shareholders' Equity | -3.47M | -3.59M | - | 1.48B | -275K | -294K | -22.6K | -36.4K | -94.2K | - | -191K |
| Cash & Short-term Investments | - | - | - | 2.50K | - | - | 0.00 | 0.00 | 131.00 | - | 35.4K |
| Total Debt | 1.55M | 1.67M | 1.95M | - | 23.0K | 23.0K | - | - | 97.4K | - | 183K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | - | -3.80K | -3.80K | -3.80K | -32.3K | -86.8K | - | - |
| Capital Expenditure | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Free Cash Flow | - | - | - | - | 0.00 | 0.00 | -3.80K | -32.3K | -86.8K | - | - |
| Ratios | |||||||||||
| ROE | - | - | - | 0.0% | - | - | - | - | - | - | - |
| ROA | -2,716.7% | -2,466.7% | - | 0.0% | -5,433.3% | - | - | - | -1,521,431.1% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Nunzia Pharmaceutical Corporation dividends
Nunzia Pharmaceutical Corporation has not paid dividends in the last 8 fiscal years.
Last stock split: 1:7000 on Dec 4, 2019.
Who owns Nunzia Pharmaceutical Corporation
- Insiders 81.96%
- Institutions 0.00%
- Public & others 18.05%
- Shares outstanding 435M
- Free float 78.4M
Nunzia Pharmaceutical Corporation company profile
- Company name
- Nunzia Pharmaceutical Corporation
- Ticker
- NUNZ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1627 West 14th Street, Long Beach, CA, United States, 90813
- Phone
- 714 609 9117
- Website
- nunziapharma.com
About Nunzia Pharmaceutical Corporation
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.
Nunzia Pharmaceutical Corporation management
3- Mr. Michael MitsunagaPresident, CFO, Treasurer, Secretary & Director · born 1957
- Dr. Shujie CuiChief Medical Officer, Chief Science Officer & Director · born 1965
- Ms. Sara P. GonzalesCEO & Director · born 1973